Pfizer’s Financial Results Beat Wall Street Expectations

Pharmaceutical giant Pfizer (PFE) has reported financial results for this year’s second quarter that topped Wall Street forecasts.

The New York City-based company announced earnings per share (EPS) of $0.78 U.S., which topped the $0.58 U.S. consensus expectation of analysts.

Revenue in the April through June period totaled $14.65 billion U.S., which was ahead of the $13.56 billion U.S. forecast on Wall Street.

The strong results come after Pfizer undertook several cost-cutting efforts, which were aimed at helping the pharmaceutical giant recover from the rapid decline of its Covid-19 business.

Pfizer has said it expects to deliver $7.7 billion U.S. in savings by the end of 2027.

The results also come as Pfizer grapples with U.S. President Donald Trump’s demands to lower drug prices in the U.S. and braces for planned tariffs on imported medications.

In April, Pfizer executives said the company’s 2025 guidance included $150 million U.S. in expected costs from tariffs.

As part of its Q2 print, Pfizer raised its forward guidance, saying it now expects a full-year profit of $2.90 U.S. to $3.10 U.S., up from a previous outlook of $2.80 U.S. to $3 U.S. a share.

The company maintained its 2025 revenue outlook of $61 billion U.S. to $64 billion U.S. in sales

PFE stock is down 12% so far in 2025 and trading at $23.53 U.S. a share.